Preventing adverse health effects of environmental chemical exposure is fundamental to protecting individual and public health. When done efficiently and properly, chemical risk assessment enables risk management actions that minimize the incidence and effects of environmentally induced diseases related to chemical exposure. However, traditional chemical risk assessment is faced with multiple challenges with respect to predicting and preventing disease in human populations, and epidemiological studies increasingly report observations of adverse health effects at exposure levels predicted from animal studies to be safe for humans. This discordance reinforces concerns about the adequacy of contemporary risk assessment practices for protecting public health.
It is becoming clear that to protect public health more effectively, future risk assessments will need to use the full range of available data, draw on innovative methods to integrate diverse data streams, and consider health endpoints that also reflect the range of subtle effects and morbidities observed in human populations.
Considering these factors, there is a need to reframe chemical risk assessment to be more clearly aligned with the public health goal of minimizing environmental exposures asso- or the past several decades, human health risk assessment has been a pillar of environmental health protection. In general, the products of risk assessment have been numerical risk values derived from animal toxicology studies of observable effects at high doses of individual chemicals. Although this approach has contributed to our understanding of overt health outcomes from chemical exposures, it does not always match our understanding from epidemiology studies of the consequences of real-world exposures in human populations, which are characterized by exposure to multiple pollutants, often chronically, at concentrations that can fluctuate over wide ranges; susceptible populations and life stages; potential interactions between chemicals and nonchemical stressors and background disease states; and lifestyle factors that modify exposures (e.g., airtight houses). 1 These and other issues are particularly important when determining risk of complex diseases, such as cardiovascular disease. Ten years ago, the National Research Council offered a new paradigm for evaluating the safety of chemicals on the basis of chemical characterization, testing using a toxicity pathway approach, and modeling and extrapolating the dose-response relationship from in vitro testing, all embedded in a risk context and considering populationbased data and exposure.
2 Efforts such as the Tox21 Consortium 3, 4 and ToxCast program 5 have helped us better understand the biological interactions of large numbers of chemicals using high-throughput assay systems, and we are witnessing early adoption of new technologies and approaches for screening chemicals for integrated testing. 6 Several other factors are also changing the way environmental health professionals think about chemical risks and how to most effectively protect public health, especially for complex diseases like cardiovascular disease. It is estimated that intrinsic factors (e.g., those that result in mutations stemming from random errors in DNA replication) account for only 10% to 30% of many common cancers. 7 Similarly, only 30%
to 40% of birth defects can be attributed to known causes such as genetics, fetal alcohol syndrome, maternal smoking, and folate insufficiency. 8 Other studies have concluded that nongenetic environmental factors and gene by environment interactions are the primary causes of chronic diseases. 9 The ability to evaluate and quantify the role of environmental factors on public health is a clear opportunity, but it is limited by the lack of readily available models for prominent clinical outcomes.
CURRENT CHALLENGES
Understanding public health risk from environmental chemical exposures is complicated by many factors, such as population variability and susceptibility, long latencies between critical exposures and disease manifestations, and background environmental exposures. Issues of population variability and susceptibility are poorly understood and difficult to characterize and incorporate into risk assessments. For example, a person's unique microbiome may modulate his or her response to environmental exposures. 10, 11 Although studies are limited in this emerging area, knowledge about the microbiome may inform interindividual variability and unexplained susceptibility observed in populations. Scientists have begun to appreciate the role of the microbiome in the lack of reproducibility and interpretability of animal studies. 12 Another example is the effects of early life environmental exposures on health outcomes later in life. Advances in the field of epigenetics have revealed that developmental exposure to endocrine disrupting chemicals can alter epigenetic programming of gene regulation and thus may play a role in the risk of obesity later in life. 13 To fully realize the potential of adverse outcome pathwaybased approaches and to integrate biological findings across disciplines, we must strengthen our ability to detect precursor events in human populations and to identify biologically relevant exposure metrics, ideally measurable in individuals. Another advancement that has a great potential to advance our understanding of data-poor chemicals is the use of nontesting approaches (e.g., quantitative structure-activity relationship) that allow us to predict toxicity when adequate testing data are absent-especially when we combine knowledge of chemical structural features and in vitro bioactivity determinations. Advances in the development of chemical libraries, cheminformatics, and read-across predictions and integration with molecular data and adverse outcome pathways have significantly improved their application and predictive capacity, which will allow more comprehensive assessment of the health effects of exposures. 17, 18 Effectively predicting population risk by integrating a variety of data streams (e.g., epidemiology, toxicology, high-throughput testing) and considering multiple sources and pathways of exposure can better inform environmental public health decisions. Advances in technology and computational capabilities have fostered new opportunities for generating and analyzing molecular, animal, and human data on effects and exposures, which can be integrated 
16 Figure 1 presents a conceptual model for a public health perspective for risk assessment.
Although approaching assessments from the perspective of health outcomes may be challenging, it provides the opportunity to evaluate exposures and effects across the life span that are relevant to population health. Advances in science and technology, such as adverse outcome pathway development, the broader availability of chemical and biological data, and the applications of statistical and bioinformatics tools, bring this previously aspirational approach well within reach.
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EXAMPLE: CARDIOVASCULAR DISEASE
A public health approach may inform the challenge of cardiovascular disease. Cardiovascular disease is the number 1 cause of mortality worldwide and is a major US public health burden. 21, 22 Annual costs of cardiovascular disease in the United States were estimated to be $317 billion in 2011 and 2012, considering direct medical costs and lost productivity because of premature mortality. 22 This estimate is likely to substantially underestimate the social cost of cardiovascular disease because of limitations in the estimation of indirect costs associated with morbidity and premature mortality. 23 Although much is known about the biochemical and behavioral risk factors associated with cardiovascular disease, particularly compared with other diseases and health conditions, the traditional risk factors fail to account for 10% to 25% of its prevalence. 24 Environmental factors, including air pollution 25 and chemical exposures 26 are thought to contribute to the unexplained fraction. Although mortality stemming from cardiovascular disease has decreased over the past few decades in the developed world as a result of reductions in behavioral risk factors, the rising prevalence of obesity and diabetes might account for the deceleration in the rate of improvement in annual cardiovascular mortality in the United States over the past few years. 27 There is an urgent need to better understand the biological pathways through which environmental exposures to chemical and nonchemical stressors act to stimulate and accelerate atherosclerosis and promote adverse cardiovascular health effects. Applying the adverse outcome pathway framework, 28 the initial molecular response to a chemical exposure will often be receptor 
Traditional Risk Assessment
Note. This conceptual model illustrates how the starting point in a public health-focused risk assessment would differ from that of traditional risk assessment. In traditional risk assessment, the starting point is focused on specific chemicals or classes of chemicals of concern, with multiple data streams saying what the critical effects from that chemical are. A public health perspective would focus on the adverse health outcome of concern with multiple data streams, informing our understanding of hazard and exposure in the context of public health decisions related to that outcome and not necessarily focused on just 1 chemical or class of chemicals. Figure 2 ). Over time, these changes produce subclinical effects, such as changes in electrical and mechanical cardiac function, vascular function, and nonobstructive atherosclerotic vascular changes. With the persistence of metabolic changes that stimulate the progression of vascular disease, clinical cardiovascular events such as heart attacks, strokes, heart failure, and abnormal heart rhythms follow. To date, the most comprehensive application of this approach has been in the study of population-level health effects of air pollution exposure. 28 Epidemiological data at the population level has provided support that air pollutant exposure (e.g., ambient particular matter and NO 2 ) accelerates the development and progression of coronary atherosclerosis. 25 Xenobiotic metals such as arsenic, cadmium, lead, and mercury are also associated with atherosclerosis. 29 Geneenvironment interaction alters the risk of vascular disease 30 ; for example, the residential proximity to highways (representing exposure to a mixture of trafficrelated air pollutants) is associated with peripheral vascular disease, which is modified by the gene encoding bone morphogenic protein. 7, 31 Because of the complexity of the drivers of atherosclerosis, a medical model treating blood pressure and high cholesterol and advising dietary modification and exercise will be inadequate to fully address this disease. Likewise, identifying the chemicals that increase risk on an individual basis will be inadequate to prevent vascular disease. Instead an integrated systems approach is 
Individual Health Burden
Source. Action of specific chemicals and metals adapted from Kirkley and Sargis. 26 Note. As = Arsenic; AO = adverse outcome; BaP = benzo[a]pyrene; BPA = bisphenol A; Cd = Cadmium; DEHP = di(2-ethylhexyl) phthlate; DES = diethylstilbestrol; HDL = highdensity lipoprotein; IKE = intermediate key event; LDL = low-density lipoprotein; PCB = polychlorinated biphenyl; PFOS = perfluorooctane sulfonic acid; PM 2.5 = particulate matter £ 2.5 mm; TCDD = tetrachlorodibenzo-p-dioxin. This figure illustrates the biological pathway leading from exposure to adverse cardiovascular outcomes for a variety of chemicals. On the left-hand side of the figure these pathways are linked to the adverse outcome pathway, and on the right-hand side of the figure we see the traditional risk factors for adverse cardiovascular outcomes.
FIGURE 2-Adverse Outcome Pathway for Cardiovascular Outcomes needed to fully account for all known risk factors and formulate the problem to define the most effective strategy to decrease individual risk and societal burden. Accomplishing this will require clinical data that fully reflect a population under consideration as well as exposures to traditional risk factors, biomonitoring data documenting exposures to multiple chemicals, and molecular responses from in vitro and in vivo studies indicative of the activation of biochemical pathways that accelerate atherosclerosis. Although this approach might not be practical currently, it is not unrealistic to think about future states where it could become standard practice. Our proposed innovative approach to chemical risk assessment is occurring contemporaneously during the formative stages of the National Institutes of Health-sponsored Precision Medicine Initiative, which will drive integration of genomics, data sciences, and bioinformatics as the basis for improved individual health care, disease prevention, and public health. The Affordable Care Act has accelerated electronic medical record adoption in health care practices and hospital systems, potentially offering a valuable source of information for population-level health monitoring. Recent research has used big data to study the early stages of disease and better classify and predict disease progression and could be used to inform personalized medicine to optimize wellness in healthy populations. [32] [33] [34] Moreover, the anticipated integration and development of technologies and analytical tools have the potential to improve public health and increase the spatial and temporal resolution of environmental health surveillance. The establishment of a long-term representative precision medicine cohort, if integrated with the proposed National Biomonitoring Network, 35 could have enormous benefit in helping us understand the relationship between chemical exposures and disease and in managing some of the most challenging clinical problems more effectively. Applying this framework would potentially expand our understanding of the origins of vascular disease and its progression, helping define strategies for primary prevention to thwart the initiation of the process we ultimately call atherosclerosis. Thus, such a framework would provide new and ongoing insights into the associations between environmental exposures that contribute the greatest burden to public health. This approach would facilitate accounting for sensitive populations and could inform suggested individual health or behavioral measures in which there have been past exposures or in which current exposure cannot be reduced enough to protect those most at risk.
CONCLUSIONS
The proposed conceptual model is grounded in public health principles and focused on identifying the greatest opportunity to reduce environmental exposures to improve health outcomes. Along with traditional risk assessment, this perspective can better inform public health decision-making. Although there are clear benefits to operating within a public healthfocused framework and moving away from individual chemicals and apical endpoints, there are also challenges.
Informing DecisionMaking
Since the 1980s, the Environmental Protection Agency's decision-making has been grounded on traditional risk assessments that are conducted within the constraints of the Environmental Protection Agency's statutes and programs. Although program-targeted risk assessments will remain an important component, the diseasebased approach draws on information in a holistic fashion that cuts across organizational and legal boundaries, integrating traditional inputs and newer data streams. These assessments will provide decision-makers with critical information to inform exposure-reduction efforts to affect the selected health outcomes and, ultimately, improve public health. Because those exposure-reduction efforts would take place within the existing statutory construct, an important implementation step would be to move from findings of disease-based risk assessments to assessments of specific risk management actions under the relevant statutory authorities.
Priorities for Screening and Testing
A health outcome-focused framework can inform priorities for screening and testing the toxicity of chemicals. Efforts to develop and synthesize approaches for screening large numbers of chemicals using high-throughput toxicity testing and exposure prediction should continue to provide data for data-poor chemicals. For example, in the recently announced Cancer Moonshot, 36 high-throughput approaches could screen a large set of chemicals for potential carcinogenicity and identify a suite of chemicals for additional animal toxicity testing.
Examining noncancer endpoints will also be challenging, which is why developing adverse outcome pathways and networks to contextualize and interpret nonapical hazard data in relation to population health is of increasing value. Epidemiology studies can be designed to inform and validate high-throughput testing approaches by identifying both chemical stressors and nonchemical stressors that modify responses to chemical exposures; they can also be designed to test relationships between disease and early markers of exposure and biological response (e.g., epigenetic changes).
The Impact of Cumulative Exposures
Although cumulative risk assessment has been of high interest for the past few decades, putting cumulative assessment approaches into practice has been challenging. This framework provides a new construct for considering cumulative risk. By focusing on a health endpoint of concern, one could consider the multiple exposures that may contribute to a health outcome. Past National Research Council recommendations have encouraged assessors to evaluate the combined effects of exposures to all chemicals that affect a common adverse outcome, for example, male reproductive development. 37 Challenges include gaining adequate understanding of individual chemical effects to group chemicals by health outcome. Increased research into the biological pathways by which chemicals affect health status can help inform approaches for estimating the joint effect of chemicals without testing all permutations or combinations.
One example of an alternative approach is health impact assessment, which uses a systems approach to array data sources and analytic methods and considers input from stakeholders to determine potential effects of a proposed action or decision on the health of a population and the distribution of those effects in the population. 38 Using health impact assessment approaches for chemical risk assessments made through this framework can offer a method to organize various data streams that can influence our understanding of a health effect, inform potential multiple contributors to adverse health outcomes, and provide recommendations to decision-makers for monitoring and managing these outcomes.
Consider Public Health Concepts
This new approach takes a systematic view of collective factors that contribute to a health outcome or disease state, including those that are not regulated by a single federal entity. Any single health outcome may be influenced by multiple factors beyond chemical exposures, such as nutrition, genetics, and social stressors. Because those factors are not regulated, it is important for environmental regulatory agencies to understand what fraction of the disease burden is influenced by the regulated environmental exposure.
Public health approaches, such as attributable risk, can help inform this understanding. Challenges may include incorporating these approaches, which are typically used in epidemiology, to animal and advanced toxicity testing data; ensuring adequate training with the approaches; and communicating risk in a way that acknowledges the influence of nonregulated factors.
Public Health Implications
Understanding the health effects of chemicals has real implications for public health. This proposed approach for chemical risk assessment starts at the health endpoint and incorporates multiple data streams, including data developed using newer technologies such as high-throughput screening. In parallel with more traditional risk assessment approaches, this will lead to a better understanding of mechanisms of single chemicals as well as cumulative exposures that lead to specific disease endpoints.
This new lens will need to be applied to the complete risk assessment process-problem formulation, data considerations, and data synthesis through multipathway methods, including cumulative assessment and health impact assessment-with an eye to the prevention of adverse effects. This approach draws on the best available science to improve our understanding of the health effects of environmental chemicals and informs decisionmaking to prevent, reduce, or mitigate exposure and ultimately improve public health. 
